Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Alfa eCare in connection with the acquisition of 2BRA
Mandate

Vinge advises Main Capital and Alfa eCare in connection with the acquisition of 2BRA

January 02, 2023 Employment and Benefits IT, Telecommunications and Outsourcing Intellectual Property M&A Life Sciences & Health

The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.

2BRA System AB was founded in 2008 and develops business systems used for labour market measures and initiatives. The company’s services are provided companies that support people in establishing themselves in the labor market and to municipalities, where the company’s system today is used in over 100 municipal operatios. The acquisition of 2BRA is the sixth acquisition by the Alfa eCare group since Main Capital became majority owners of the group in 2020.

Vinge’s team advising Main Capital and Alfa eCare mainly consisted of Filip Öhrner, Linus Adolfsson, Jonna Skog (M&A), Elin Broman (Employment), Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Ottilia Pettersson (project assistant).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025